MetaCap

CalciMedica (CALC) vs Vyome (HIND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vyome (HIND) has outperformed CalciMedica (CALC) over the past year, losing 75.9% versus a loss of 92.3%. CalciMedica is the larger company by market cap ($8.7 million vs $8.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CALC-92.34%HIND-75.90%
+115%+6%-104%
Nov 21, 20251 yearNov 20, 2026
CALC-94.99%HIND-99.99%
+41%-33%-107%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CALC versus HIND key metrics
MetricCALCHIND
Share price$1.26$1.20
Market cap$8.69M$8.42M
1-day change+7.69%-17.24%
YTD return-96.18%-65.12%
1-year return-92.34%-75.90%
5-year return—-100.00%
P/E ratio (TTM)—0.25
EPS (TTM)$-4.41$4.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$319.71K
Revenue growth (YoY)—+24.43%
Net income (latest FY)$-29.56M$-10.26M
Gross margin—68.43%
Operating margin—-3269.35%
Net margin—-3209.75%
52-week high$36.00$5.88
52-week low$1.00$1.20
Distance from 52-week high-96.50%-79.59%
Analyst consensusnonestrong_buy
Avg. price target upside+3868.25%+635.83%
Average volume80.15K13.92K
Shares outstanding6.90M7.02M
Employees159
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HIND has outperformed CALC by 16.4 percentage points over the past year.

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Vyome

HIND stock →

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

CALC vs HIND FAQ

Which is bigger, CalciMedica or Vyome?

CalciMedica (CALC) is larger, with a market capitalization of $8.69M compared with $8.42M for Vyome (HIND).

Which stock has performed better over the past year, CALC or HIND?

HIND returned -75.90% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are CalciMedica and Vyome in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons